Akoya Biosciences, Inc. - AKYA Total Company Value-to-Revenue Ratio

Akoya Biosciences (AKYA) - corporate logo

The high credit potential of Akoya Biosciences (AKYA) is based on regular sales of high-margin reagents. The EV-to-revenue ratio demonstrates moderate volatility, and the value of captures this metric. Financial stability is bolstered by oncologists' demand for personalized medicine and the combination of software solutions with unique consumables for modern IT laboratories.

Akoya Biosciences (AKYA) EV/Sales Multiple: for the period 07/04/2022 - 11/20/2026

Financial and market metric breakdowns for Akoya Biosciences, Inc. (AKYA)

- share price and consensus valuation forecast:
Fundamental company valuation:AKYA, Akoya
Flagship merchandise of akoyabio.com

This metric compares the total enterprise value to sales volume, neutralizing the impact of debt load to provide an objective assessment of the market pricing coefficient. An analysis of Akoya Biosciences (AKYA) valuation via the EV/Sales multiple helps determine the fairness of its capitalization, considering the high value of PhenoCycler patents and stringent FDA requirements, which create significant barriers to entry for competitors and define the long-term value of the assets.